8-K: Enhabit Reports Mixed Q4 Results, Provides Full-Year 2024 Guidance

Enhabit reported a net loss for the fourth quarter of 2023, despite growth in home health admissions and hospice revenue, and issued full-year 2024 guidance.

Summary

• Enhabit, a home health and hospice care provider, announced its fourth-quarter results for 2023, showing a net loss of $6.4 million.
• The company's adjusted EBITDA was $25.2 million, a decrease compared to $30.3 million in the same quarter of the previous year.
• Home health net service revenue was $209.5 million, down 2.9% year-over-year, while hospice net service revenue increased by 7.8% to $51.1 million.
• Non-episodic home health admissions grew significantly by 34.2%, driving total admission growth of 3.9%.
• The company finalized 11 new Medicare Advantage agreements during the quarter and added a new national advanced episodic agreement effective January 1, 2024.
• Enhabit's 30-day hospitalization readmission rate in home health was 20.5% better than the national average.
• Hospice cost per day decreased to $76 after stabilizing at $77 for the prior three quarters.
• The company provided full-year 2024 guidance, projecting net service revenue between $1,076 and $1,102 million, adjusted EBITDA between $98 and $110 million, and adjusted EPS between $0.12 and $0.43.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positive aspects like growth in non-episodic admissions and new contracts, the net loss, decreased EBITDA, and the negative impact of the payor mix shift temper the overall outlook.

Positives

• Non-episodic home health admissions saw a significant increase of 34.2% year-over-year.
• Hospice revenue increased by 7.8% year-over-year.
• The company successfully negotiated 11 new Medicare Advantage agreements in the fourth quarter.
• Enhabit's 30-day hospitalization readmission rate in home health is significantly better than the national average.
• Hospice cost per day decreased to $76 in Q4 2023.
• The company has seen a 21.5% increase in the full-time nursing candidate pool year-over-year.
• Enhabit opened two new de novo locations in the fourth quarter.

Negatives

• The company reported a net loss of $6.4 million for the fourth quarter of 2023.
• Adjusted EBITDA decreased by 16.8% year-over-year.
• Home health net service revenue decreased by 2.9% year-over-year.
• The shift to more non-episodic admissions in home health negatively impacted revenue and Adjusted EBITDA by approximately $8 million.
• Adjusted EPS decreased by 64.7% year-over-year.
• Home health revenue per episode decreased by 1.1% year-over-year.
• Hospice average daily census decreased by 4.3% year-over-year.

Risks

• The continued shift to more non-episodic admissions in home health is impacting revenue and profitability.
• Changes in reimbursement rates could affect the company's financial performance.
• The company faces risks related to attracting and retaining key management and healthcare professionals.
• Potential disruptions or breaches of information systems could negatively impact operations.
• The outcome of litigation could have an adverse effect on the company.
• The company's ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures is a risk.
• The company's ability to control costs, particularly labor and employee benefit costs, is a risk.
• The company's strategic review process and the potential for a strategic transaction on attractive terms or at all is a risk.

Future Outlook

The company provided full-year 2024 guidance, projecting net service revenue between $1,076 and $1,102 million, adjusted EBITDA between $98 and $110 million, and adjusted EPS between $0.12 and $0.43. The guidance includes considerations for Medicare pricing increases, the shift to non-episodic admissions, and cost per visit and day increases.

Management Comments

• Enhabit's President and Chief Executive Officer, Barb Jacobsmeyer, stated that the company's strategies drove positive fourth-quarter results.
• She highlighted payor innovation success, the company's people strategy, and strong performance in quality outcomes as key achievements.
• She expressed excitement about the company's future and its ability to meet the growing demand for home health and hospice services.

Industry Context

The announcement reflects the ongoing trends in the home health and hospice industry, including the shift towards value-based care models, the increasing importance of Medicare Advantage plans, and the need for efficient and high-quality care delivery. The company's focus on payor innovation and cost management aligns with these industry trends.

Comparison to Industry Standards

• Enhabit's 30-day hospital readmission rate in home health is 20.5% better than the national average, indicating a strong performance in patient care quality compared to industry benchmarks.
• The company's hospice patient visits in the last days of life are 53.2% better than the national average, demonstrating a commitment to end-of-life care.
• The company's focus on payor innovation and securing new Medicare Advantage agreements is a common strategy among home health and hospice providers to improve revenue and profitability.
• The company's cost per visit in home health remained flat year-over-year, which is a positive sign in an industry facing increasing labor costs.
• The company's hospice cost per day decreased to $76 in Q4 2023, which is a positive sign in an industry facing increasing labor costs.
• The company's growth in non-episodic admissions reflects a broader industry trend of increasing demand for home-based care for patients with chronic conditions.

Stakeholder Impact

• Shareholders may be concerned about the net loss and decreased profitability.
• Employees may be impacted by the company's focus on cost management and efficiency.
• Customers (patients) may benefit from the company's focus on quality outcomes and patient experience.
• Payors may be interested in the company's payor innovation strategy and its ability to manage costs.
• Suppliers may be affected by the company's cost management initiatives.

Next Steps

• The company will host an investor conference call on March 7, 2024, to discuss the fourth-quarter results.
• The company will focus on stabilizing Medicare as a percentage of total home health revenue.
• The company will leverage its payor innovation strategy.
• The company will improve Medicare Advantage rates.
• The company will shift away from lower rate contracts.
• The company will grow through increased clinical staffing.
• The company will grow census through improved staffing capacity with case management model.
• The company will gain operating leverage in hospice fixed cost structure by growing census.
• The company will increase use of analytics to drive high-quality care via case management model.
• The company will focus on efficiencies in referral to admission process.
• The company will open 10 de novo locations.
• The company will ramp up staffing, referral and admission growth in de novo locations opened in 2023.
• The company will continue to increase net full-time nursing and therapy headcount to support home health growth.
• The company will focus on employee engagement to retain workforce.

Key Dates

Keywords

home health, hospice, Medicare Advantage, non-episodic admissions, adjusted EBITDA, net service revenue, healthcare, payor innovation, readmission rate, de novo locations